Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The FDA has approved BMS’s Daklinza (daclatasvir) to be used with Gilead Sciences’ Sovaldi (sofosbuvir) to treat genotype 3 of hepatitis C.
Those coinfected with HIV and genotype 3 of hepatitis C responded about
the same to interferon and ribavirin as those with only hep C in a...
Alisporivir, a once-daily drug being developed by Novartis at the forefront of a new class of hepatitis C virus (HCV) compounds known as cyclo...
A twelve-week course of Pharmasset’s once-daily experimental nucleotide analog PSI-7977, combined with ribavirin, cured 10 of 10 people living...
People with HIV and hepatitis C virus (HCV) and who achieve undetectable HCV levels after only four weeks of HCV treatment may be able to clea...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.